Ulcerative colitis: STRIDE-ing beyond symptoms with new standards

Area of Science:

• Gastroenterology and Inflammatory Bowel Disease Research

Background:

• The management of ulcerative colitis (UC) has significantly evolved over the past 20 years.
• Pharmacotherapeutic advancements have introduced novel treatment options, with numerous agents currently under development.
• Increased understanding of inflammatory pathways has enabled targeted drug therapies, leading to improved clinical outcomes through enhanced disease control.

Purpose of the Study:

• To review the advancements in ulcerative colitis treatment over the last two decades.
• To highlight the shift in treatment goals towards achieving endoscopic and histological healing.
• To emphasize the importance of disease activity control in mitigating colorectal cancer risk.

Main Methods:

• Review of recent literature on ulcerative colitis pharmacotherapeutics and treatment strategies.
• Analysis of the impact of new treatment targets on patient outcomes.
• Evaluation of updated colorectal cancer screening guidelines in the context of inflammatory bowel disease.

Main Results:

• Significant progress in pharmacotherapeutics has led to new treatment options for ulcerative colitis.
• A paradigm shift in treatment targets from symptom management to achieving endoscopic and histological remission.
• Effective disease control in ulcerative colitis is associated with a reduced risk of colorectal cancer development.

Conclusions:

• Modern ulcerative colitis management prioritizes achieving deeper remission, including endoscopic and histological healing.
• Controlling disease activity is crucial for improving patient outcomes and preventing complications like colorectal cancer.
• Enhanced diagnostic tools, such as dye-based chromoendoscopy and high-definition colonoscopy, are vital for accurate colorectal cancer screening in UC patients.